AMGEVITA 40 mg SOLUTION FOR INJECTION IN PRE-FILLED PEN

Introduction

Package Leaflet: Information for the Patient

AMGEVITA 40mg solution for injection in pre-filled pen

Adalimumab

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

• Keep this leaflet, you may need to read it again.
• Your doctor will give you a patient information card, which contains important safety information that you need to know before and during treatment with

AMGEVITA. Keep this patient information card.

• If you have any further questions, ask your doctor or pharmacist.
• This medicine has been prescribed for you only. Do not pass it on to others, even if they have the same symptoms as you, as it may harm them.

If you experience any side effects, talk to your doctor or pharmacist, even if it is not listed in this leaflet. See section 4.

Contents of the pack

1. What is AMGEVITA and what is it used for
2. What you need to know before you use AMGEVITA
3. How to use AMGEVITA
4. Possible side effects
5. Storing AMGEVITA
6. Contents of the pack and further information

1. What is AMGEVITA and what is it used for

AMGEVITA contains the active substance adalimumab, a medicine that works on the body's immune system (defense).

AMGEVITA is indicated for the treatment of inflammatory diseases described below:

• Rheumatoid arthritis
• Juvenile idiopathic polyarticular arthritis
• Enthesitis-related arthritis
• Ankylosing spondylitis
• Non-radiographic axial spondyloarthritis
• Psoriatic arthritis
• Plaque psoriasis
• Hidradenitis suppurativa
• Crohn's disease
• Ulcerative colitis
• Non-infectious uveitis

The active substance in AMGEVITA, adalimumab, is a human monoclonal antibody. Monoclonal antibodies are proteins that target a specific target.

The target of adalimumab is a protein called tumor necrosis factor (TNFα), which is involved in the immune system (defense) and is found in high levels in the inflammatory diseases described above. By targeting TNFα, AMGEVITA reduces the inflammation process in these diseases.

Rheumatoid arthritis

Rheumatoid arthritis is an inflammatory disease of the joints.

AMGEVITA is used to treat rheumatoid arthritis in adults. If you have moderate to severe active rheumatoid arthritis, you may have been given other disease-modifying medicines such as methotrexate beforehand. If you do not respond well enough to these medicines, you will be given AMGEVITA to treat your rheumatoid arthritis.

AMGEVITA can also be used to treat severe, active, and progressive rheumatoid arthritis without prior treatment with methotrexate.

AMGEVITA reduces the damage to the cartilage and bones of the joints caused by the disease and improves physical function.

AMGEVITA is usually used in combination with methotrexate. If your doctor decides that methotrexate is not suitable, AMGEVITA can be given alone.

Juvenile idiopathic polyarticular arthritis and enthesitis-related arthritis

Juvenile idiopathic polyarticular arthritis and enthesitis-related arthritis are inflammatory diseases of the joints that usually appear for the first time in childhood.

AMGEVITA is used to treat juvenile idiopathic polyarticular arthritis in patients from 2 years of age and enthesitis-related arthritis in patients from 6 years of age. You may have been given other disease-modifying medicines such as methotrexate beforehand. If you do not respond well enough to these medicines, you will be given AMGEVITA to treat your juvenile idiopathic polyarticular arthritis or enthesitis-related arthritis.

Ankylosing spondylitis and non-radiographic axial spondyloarthritis

Ankylosing spondylitis and non-radiographic axial spondyloarthritis are inflammatory diseases that affect the spine.

AMGEVITA is used to treat ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults. If you have ankylosing spondylitis or non-radiographic axial spondyloarthritis, you will be treated first with other medicines and if you do not respond well enough to these medicines, you will be given AMGEVITA to reduce the signs and symptoms of your disease.

Psoriatic arthritis

Psoriatic arthritis is an inflammation of the joints associated with psoriasis.

AMGEVITA is used to treat psoriatic arthritis in adults. AMGEVITA reduces the joint damage caused by the disease in the cartilage and bone and improves physical function.

Plaque psoriasis in adults and children

Plaque psoriasis is a skin disease that causes red, scaly, crusty, and silvery-scaled areas. Plaque psoriasis can also affect the nails, causing them to deteriorate, thicken, and lift off the nail bed, which can be painful. It is believed that psoriasis is caused by a defect in the body's immune system that leads to an increase in the production of skin cells.

AMGEVITA is used to treat moderate to severe plaque psoriasis in adults. AMGEVITA is also used to treat severe plaque psoriasis in children and adolescents between 4 and 17 years of age who have not responded or are not suitable candidates for topical treatment and phototherapies.

Hidradenitis suppurativa in adults and adolescents

Hidradenitis suppurativa (also known as inverse acne) is a chronic and often painful inflammatory skin disease. Symptoms can include painful nodules (lumps) and abscesses (boils) that can secrete pus. It usually affects specific areas of the skin, such as under the breast, armpits, inner thighs, groin, and buttocks. There may also be scarring in the affected areas.

AMGEVITA is used to treat hidradenitis suppurativa in adults and adolescents from 12 years of age. AMGEVITA can reduce the number of nodules and abscesses, and the pain that is usually associated with this disease. You may have been given other medicines beforehand. If you do not respond well enough to these medicines, you will be given AMGEVITA.

Crohn's disease in adults and children

Crohn's disease is an inflammatory disease of the digestive tract.

AMGEVITA is used to treat Crohn's disease in adults and children between 6 and 17 years of age. If you have Crohn's disease, you will be treated first with other medicines. If you do not respond well enough to these medicines, you will be given AMGEVITA to reduce the signs and symptoms of Crohn's disease.

Ulcerative colitis in adults and children

Ulcerative colitis is an inflammatory disease of the large intestine.

AMGEVITA is used to treat moderate to severe ulcerative colitis in adults and children between 6 and 17 years of age. If you have ulcerative colitis, you may be given other medicines first. If you do not respond well to these medicines, you will be given AMGEVITA to reduce the signs and symptoms of your disease.

Non-infectious uveitis in adults and children

Non-infectious uveitis is an inflammatory disease that affects certain parts of the eye.

AMGEVITA is used to treat

• Adults with non-infectious uveitis with inflammation that affects the back of the eye.
• Children from 2 years of age with chronic non-infectious uveitis with inflammation that affects the front of the eye.

This inflammation can lead to a decrease in vision and/or the presence of floaters in the eye (black dots or thin lines that move along the field of vision). AMGEVITA works by reducing this inflammation.

2. What you need to know before you start using AMGEVITA

Do not use AMGEVITA

• if you are allergic to adalimumab or to any of the other components of this medicine (listed in section 6).
• if you have a severe infection, including active tuberculosis, sepsis (blood infection), or other opportunistic infections (unusual infections associated with a weakened immune system (see "Warnings and precautions"). If you have symptoms of any infection, such as fever, wounds, fatigue, or dental problems, it is essential that you inform your doctor.
• if you have moderate or severe heart failure. It is crucial that you tell your doctor if you have had or have any serious heart problems (see "Warnings and precautions").

Warnings and precautions

Consult your doctor or pharmacist before starting to use AMGEVITA:

Allergic reactions

• If you notice an allergic reaction with symptoms such as chest tightness, difficulty breathing, dizziness, swelling, or rash, discontinue the administration of AMGEVITA and contact your doctor immediately, as these reactions can be life-threatening in rare cases.

Infections

• If you have any infection, including chronic or localized infections (e.g., a leg ulcer), consult your doctor before starting treatment with AMGEVITA. If you are unsure, contact your doctor.
• With AMGEVITA treatment, you may be more likely to get infections. This risk may be higher if you have damaged lungs. These infections can be severe and include tuberculosis, viral, fungal, parasitic, or bacterial infections, and other opportunistic infections and sepsis that can, in rare cases, be life-threatening. For this reason, it is essential that if you have symptoms such as fever, wounds, fatigue, or dental problems, you inform your doctor. Your doctor may recommend that you temporarily discontinue treatment with AMGEVITA.

Tuberculosis

• Since cases of tuberculosis have been reported in patients treated with adalimumab, your doctor will examine you for signs or symptoms of tuberculosis before starting your treatment with AMGEVITA. This includes a thorough medical evaluation, including your medical history and appropriate diagnostic tests (e.g., chest X-ray and tuberculin test). The performance and results of these tests must be recorded in your patient information card. It is crucial that you inform your doctor if you have had tuberculosis or have been in contact with a tuberculosis patient.
• Tuberculosis can develop during treatment, even if you have received preventive treatment for tuberculosis.
• If symptoms of tuberculosis (persistent cough, weight loss, general malaise, low-grade fever) or any other infection appear during or after treatment, contact your doctor immediately.

Recurrent/Travel-related infections

• Inform your doctor if you live or travel to regions where fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic.
• Inform your doctor if you have a history of recurrent infections or other conditions or factors that increase the risk of infections.

Hepatitis B virus

• Inform your doctor if you are a carrier of the hepatitis B virus (HBV), if you have had active HBV infections, or if you think you may be at risk of contracting HBV. Your doctor must perform an HBV test. AMGEVITA may cause the reactivation of HBV in people carrying this virus. In rare cases, especially if you are taking other medications that suppress the immune system, HBV reactivation can be life-threatening.

Being over 65 years old

• If you are over 65 years old, you may be more susceptible to infections while being treated with AMGEVITA. Both you and your doctor should pay special attention to the appearance of signs of infection while being treated with AMGEVITA. It is essential that you inform your doctor if you have symptoms of infections, such as fever, wounds, fatigue, or dental problems.

Surgical or dental interventions

• If you are going to undergo surgery or dental procedures, inform your doctor that you are taking AMGEVITA. Your doctor may recommend that you temporarily discontinue treatment with AMGEVITA.

Demyelinating disease

• If you have or develop a demyelinating disease such as multiple sclerosis, your doctor will decide whether you should be treated or continue treatment with AMGEVITA. Inform your doctor immediately if you experience symptoms such as changes in vision, weakness in arms or legs, or numbness or tingling in any part of the body.

Vaccines

• Certain vaccines contain live, attenuated bacteria or viruses that can cause infections and should not be administered if you are being treated with AMGEVITA. Consult your doctor before administering any type of vaccine. If possible, it is recommended that children update their vaccination schedule according to current vaccination guidelines before starting treatment with AMGEVITA.
• If you receive AMGEVITA while pregnant, your child may have a higher risk of developing infections during the approximately 5 months following the last dose of AMGEVITA you received during pregnancy. It is essential that you inform your child's doctor and other healthcare professionals about your use of AMGEVITA during pregnancy, so they can decide whether your child should receive any vaccine.

Heart failure

• If you have mild heart failure and are being treated with AMGEVITA, your doctor should continuously monitor your heart failure. It is essential that you inform your doctor if you have had or have serious heart problems. If new symptoms of heart failure appear or existing ones worsen (e.g., difficulty breathing or swelling of the feet), you should contact your doctor immediately. Your doctor will decide whether you should continue taking AMGEVITA.

Fever, bruising, bleeding, or paleness

• In some patients, the body may be unable to produce a sufficient number of the type of blood cells that help the body fight infections (white blood cells) or those that contribute to stopping bleeding (platelets). If you have persistent fever, bruising, or bleeding easily, or are very pale, consult your doctor immediately. Your doctor may decide to discontinue treatment.

Cancer

• In very rare cases, certain types of cancer have been reported in children and adults treated with adalimumab or other TNF-blocking agents. People with more severe rheumatoid arthritis and those who have had the disease for a long time may have a higher-than-average risk of developing lymphoma (a cancer that affects the lymphatic system) and leukemia (a cancer that affects the blood and bone marrow).
• If you are being treated with AMGEVITA, the risk of developing lymphoma, leukemia, and other types of cancer may increase. A specific and severe type of lymphoma has been observed in rare cases in patients treated with adalimumab. Some of these patients were also receiving treatment with azathioprine or 6-mercaptopurine. Inform your doctor if you are taking azathioprine or 6-mercaptopurine with AMGEVITA.
• Additionally, cases of non-melanoma skin cancer have been observed in patients using adalimumab. Inform your doctor if new skin lesions appear or existing ones change in appearance during or after treatment.
• Cancers other than lymphoma have been reported in patients with a specific lung disease, called Chronic Obstructive Pulmonary Disease (COPD), treated with another TNF-blocking agent. If you have COPD or are a heavy smoker, you should consult your doctor about whether treatment with a TNF blocker is suitable for you.

Autoimmune diseases

• In rare cases, treatment with AMGEVITA may lead to a lupus-like syndrome. Contact your doctor if you have symptoms such as unexplained persistent rash, fever, joint pain, or fatigue.

To improve the traceability of this medicine, your doctor or pharmacist should record the name and batch number of the administered medicine in your medical history. If you are asked for this information in the future, you can also take note of these details.

Children and adolescents

• Vaccines: if possible, your child should be up-to-date with all vaccines before using AMGEVITA.
• Do not administer AMGEVITA to children with polyarticular juvenile idiopathic arthritis under 2 years of age.
• Do not administer AMGEVITA to children with plaque psoriasis under 4 years of age.
• Do not administer AMGEVITA to children with Crohn's disease or ulcerative colitis under 6 years of age.

Using AMGEVITA with other medicines

Inform your doctor or pharmacist if you are taking or have recently taken or may need to take any other medicine.

AMGEVITA can be taken with methotrexate or with certain disease-modifying antirheumatic drugs (sulfasalazine, hydroxychloroquine, leflunomide, and injectable gold salts), steroids, or pain medications, including non-steroidal anti-inflammatory drugs (NSAIDs).

Do not use AMGEVITA with medicines whose active substances are anakinra or abatacept due to an increased risk of severe infections. If you have any doubts, consult your doctor.

Pregnancy and breastfeeding

• You should consider using adequate contraceptive methods to avoid becoming pregnant and continue using them for at least 5 months after the last treatment with AMGEVITA.
• If you are pregnant, think you may be pregnant, or plan to have a baby, ask your doctor for advice on using this medicine.
• AMGEVITA should be used during pregnancy only if necessary.
• According to a pregnancy study, there was no increased risk of congenital defects when the mother had received treatment with AMGEVITA during pregnancy compared to mothers with the same disease who did not receive treatment with AMGEVITA.
• AMGEVITA can be used during breastfeeding.
• If you use AMGEVITA while pregnant, your child may have a higher risk of developing infections.
• It is essential that you inform your child's doctor and other healthcare professionals about your use of AMGEVITA during pregnancy before your child receives any vaccine. For more information on vaccines, see the "Warnings and precautions" section.

Driving and using machines

The influence of AMGEVITA on the ability to drive, ride a bicycle, or use machines is small. Dizziness and vision disturbances may occur after taking AMGEVITA.

AMGEVITA contains sodium

This medicine contains less than 1 mmol of sodium (23 mg) per 0.8 ml dose; it is essentially "sodium-free".

3. How to use AMGEVITA

Follow the administration instructions for this medication exactly as indicated by your doctor. In case of doubt, consult your doctor again.

Adults with rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or axial spondyloarthritis without radiographic evidence of ankylosing spondylitis

AMGEVITA is injected under the skin (subcutaneously). The normal dose in adults with rheumatoid arthritis, ankylosing spondylitis, axial spondyloarthritis without radiographic evidence of ankylosing spondylitis, and for patients with psoriatic arthritis is 40 mg administered every other week as a single dose.

In the case of rheumatoid arthritis, treatment with methotrexate is maintained during the use of AMGEVITA. If your doctor determines that methotrexate is inappropriate, AMGEVITA can be administered alone.

If you have rheumatoid arthritis and do not receive methotrexate during your treatment with AMGEVITA, your doctor may decide to give you 40 mg every week or 80 mg every two weeks.

Children, adolescents, and adults with polyarticular juvenile idiopathic arthritis

Children, adolescents, and adults from 2 years of age with a weight of 30 kg or more

The recommended dose of AMGEVITA is 40 mg administered every other week.

Children, adolescents, and adults with enthesitis-related arthritis

Children, adolescents, and adults from 6 years of age with a weight of 30 kg or more

The recommended dose of AMGEVITA is 40 mg every other week.

Adults with plaque psoriasis

The normal dosage in adults with plaque psoriasis consists of an initial dose of 80 mg (as two 40 mg injections on the same day), followed by 40 mg every other week starting one week after the initial dose. You should continue injecting AMGEVITA for as long as your doctor has indicated. Depending on your response, your doctor may increase the dose to 40 mg weekly or 80 mg every two weeks.

Children and adolescents with plaque psoriasis

Children and adolescents from 4 to 17 years of age with a weight of 30 kg or more

The recommended dose of AMGEVITA is an initial dose of 40 mg, followed by 40 mg one week later. From then on, the usual dose is 40 mg every other week.

Adults with hidradenitis suppurativa

The usual dosage regimen for hidradenitis suppurativa is an initial dose of 160 mg (as four 40 mg injections on the same day or two 40 mg injections per day for two consecutive days), followed by a dose of 80 mg (as two 40 mg injections on the same day) two weeks later. After two more weeks, continue with a dose of 40 mg weekly or 80 mg every two weeks, as prescribed by your doctor. It is recommended that you use an antiseptic liquid daily on the affected areas.

Adolescents with hidradenitis suppurativa from 12 to 17 years of age, with a weight of 30 kg or more

The recommended dose of AMGEVITA is an initial dose of 80 mg (as two 40 mg injections on the same day), followed by 40 mg every other week starting one week later. If you have an inadequate response to AMGEVITA 40 mg every other week, your doctor may increase the dose to 40 mg weekly or 80 mg every two weeks.

It is recommended that you use an antiseptic liquid daily on the affected areas.

Adults with Crohn's disease

The usual dosage regimen for Crohn's disease is 80 mg (as two 40 mg injections on the same day), initially, followed by 40 mg every other week starting two weeks later. If a faster response is required, your doctor may prescribe an initial dose of 160 mg (as four 40 mg injections on the same day or two 40 mg injections per day for two consecutive days), followed by 80 mg (as two 40 mg injections on the same day) two weeks later, and then 40 mg every other week. Depending on your response, your doctor may increase the dose to 40 mg weekly or 80 mg every two weeks.

Children and adolescents with Crohn's disease

Children and adolescents from 6 to 17 years of age with a weight of less than 40 kg

The usual dosage regimen is 40 mg initially, followed by 20 mg two weeks later. If a faster response is required, your doctor may prescribe an initial dose of 80 mg (as two 40 mg injections on the same day) followed by 40 mg two weeks later.

From then on, the usual dose is 20 mg every other week. Depending on your response, your doctor may increase the frequency of the dose to 20 mg weekly.

The 40 mg pre-filled pen cannot be used for the 20 mg dose. A 20 mg pre-filled syringe is available for the 20 mg dose.

Children and adolescents from 6 to 17 years of age with a weight of 40 kg or more

The usual dosage regimen is 80 mg (as two 40 mg injections on the same day) initially, followed by 40 mg two weeks later. If a faster response is required, your doctor may prescribe an initial dose of 160 mg (as four 40 mg injections on the same day or two 40 mg injections per day for two consecutive days) followed by 80 mg (as two 40 mg injections on the same day) two weeks later.

From then on, the usual dose is 40 mg every other week. Depending on your response, your doctor may increase the dose to 40 mg weekly or 80 mg every two weeks.

Adults with ulcerative colitis

The normal dosage of AMGEVITA in adults with ulcerative colitis is 160 mg initially (as four 40 mg injections on the same day or two 40 mg injections per day for two consecutive days), followed by 80 mg (as two 40 mg injections on the same day) two weeks later, and then 40 mg every other week. Depending on your response, your doctor may increase the dose to 40 mg weekly or 80 mg every two weeks.

Children and adolescents with ulcerative colitis

Children and adolescents from 6 years of age with a weight of less than 40 kg

The usual dose of AMGEVITA is 80 mg (as two 40 mg injections on the same day) initially, followed by a dose of 40 mg (as one 40 mg injection) two weeks later. From then on, the usual dose is 40 mg every other week.

Patients who turn 18 years old while receiving treatment with 40 mg every other week should continue with their prescribed dose.

Children and adolescents from 6 years of age with a weight of 40 kg or more

The usual dose of AMGEVITA is 160 mg (as four 40 mg injections on the same day or two 40 mg injections per day for two consecutive days) initially, followed by a dose of 80 mg (as two 40 mg injections on the same day) two weeks later. From then on, the usual dose is 80 mg every other week.

Patients who turn 18 years old while receiving treatment with 80 mg every other week should continue with their prescribed dose.

Adults with non-infectious uveitis

The usual dose in adults with non-infectious uveitis is an initial dose of 80 mg (as two 40 mg injections on the same day), followed by 40 mg every other week starting one week after the initial dose. You should continue injecting AMGEVITA for as long as your doctor has indicated.

In non-infectious uveitis, treatment with corticosteroids or other medications that affect the immune system may be continued during the use of AMGEVITA. AMGEVITA can also be administered alone.

Children and adolescents from 2 years of age with chronic non-infectious uveitis

Children and adolescents from 2 years of age with a weight of less than 30 kg

The usual dose of AMGEVITA is 20 mg every other week, along with methotrexate.

Your doctor may prescribe an initial dose of 40 mg that can be administered one week before starting the usual regimen.

The 40 mg pre-filled pen cannot be used for the 20 mg dose. A 20 mg pre-filled syringe is available for the 20 mg dose.

Children and adolescents from 2 years of age with a weight of 30 kg or more

The usual dose of AMGEVITA is 40 mg every other week, along with methotrexate.

Your doctor may prescribe an initial dose of 80 mg that can be administered one week before starting the usual regimen.

Form and route of administration

AMGEVITA is injected under the skin (subcutaneously).

Detailed instructions on how to inject AMGEVITA are provided in the "Instructions for use" section.

If you use more AMGEVITA than you should

If you accidentally inject AMGEVITA more frequently than prescribed by your doctor, inform your doctor. Always carry the medication box with you, even if it is empty.

If you forget to use AMGEVITA

If you forget to administer an injection, you should inject the next dose of AMGEVITA as soon as you remember. Then, the next dose will be administered as usual, as if you had not forgotten a dose.

If you interrupt treatment with AMGEVITA

The decision to stop using AMGEVITA should be discussed with your doctor. Your symptoms may return after stopping treatment.

If you have any other questions about the use of this medication, ask your doctor or pharmacist.

4. Possible side effects

Like all medications, this medication can cause side effects, although not everyone gets them. Most side effects are mild to moderate. However, some can be serious and require treatment. Side effects may appear at least up to 4 months after the last injection of AMGEVITA.

Contact your doctor immediately if you notice any of the following signs of allergic reaction or heart failure:

• severe rash, hives, or other signs of allergic reaction;
• swelling of the face, hands, feet;
• difficulty breathing, swallowing;
• shortness of breath when exercising or lying down, swelling of feet.

Contact your doctor as soon as possible if you notice any of the following effects

• signs of infection such as fever, nausea, wounds, dental problems, burning sensation when urinating;
• feeling of weakness or fatigue;
• cough;
• tingling;
• numbness;
• double vision;
• weakness in arms or legs;
• signs of skin cancer such as a lump or an open sore that does not heal;
• signs and symptoms of blood disorders such as persistent fever, bruising, bleeding, and paleness.

The symptoms described above may be signs of the following side effects, which have been observed with adalimumab.

Very common (may affect more than 1 in 10 people)

• reactions at the injection site (including pain, swelling, redness, or itching);
• respiratory tract infections (including colds, runny nose, sinusitis, pneumonia);
• headache;
• abdominal pain;
• nausea and vomiting;
• rash;
• muscle pain.

Common (may affect up to 1 in 10 people)

• serious infections (including sepsis and flu);
• intestinal infections (including gastroenteritis);
• skin infections (including cellulitis and herpes);
• ear infection;
• oral infections (including dental infection and mouth ulcers);
• infections of the reproductive system;
• urinary tract infections;
• fungal infections;
• joint infections;
• benign tumors;
• skin cancer;
• allergic reactions (including seasonal allergies);
• dehydration;
• mood changes (including depression);
• anxiety;
• difficulty sleeping;
• sensory disturbances such as tingling, itching, or numbness;
• migraine;
• nerve root compression (including lower back pain and leg pain);
• visual disturbances;
• eye inflammation;
• eyelid inflammation and eye swelling;
• vertigo (feeling of dizziness or as if the room is spinning);
• feeling of rapid heartbeat;
• high blood pressure;
• flushing;
• bruising;
• cough;
• asthma;
• difficulty breathing;
• gastrointestinal bleeding;
• indigestion (indigestion, bloating, and heartburn);
• acid reflux;
• dry eye syndrome (including dry eyes and mouth);
• itching;
• itchy rash;
• bruising;
• skin inflammation (such as eczema);
• breaking of fingernails and toenails;
• increased sweating;
• hair loss;
• new or worsening psoriasis;
• muscle spasms;
• blood in urine;
• kidney problems;
• chest pain;
• edema;
• fever;
• decrease in platelet count in blood, which increases the risk of bleeding or bruising;
• wound healing problems.

Uncommon (may affect up to 1 in 100 people)

• opportunistic infections (including tuberculosis and other infections that occur when disease resistance decreases);
• neurological infections (including viral meningitis);
• eye infections;
• bacterial infections;
• diverticulitis (inflammation and infection of the large intestine);
• cancer, including lymphoma (cancer that affects the lymphatic system) and melanoma (skin cancer);
• immune system disorders that can affect the lungs, skin, and lymph nodes (the most common presentation is sarcoidosis);
• vasculitis (inflammation of blood vessels);
• tremor;
• neuropathy;
• stroke;
• hearing loss, tinnitus;
• feeling of irregular heartbeat like skips;
• heart problems that can cause difficulty breathing or swelling of ankles;
• heart attack;
• aneurysm (balloon-like bulge in a blood vessel), inflammation, and blood clot in a vein, blockage of a blood vessel;
• lung diseases that can cause difficulty breathing (including inflammation);
• pulmonary embolism (blockage of a pulmonary artery);
• pleural effusion (abnormal fluid accumulation in the pleural space);
• pancreatitis (inflammation of the pancreas that causes severe abdominal and back pain);
• difficulty swallowing;
• facial edema;
• gallbladder inflammation; gallstones;
• fatty liver;
• night sweats;
• scars;
• abnormal muscle crisis;
• systemic lupus erythematosus (including skin inflammation, heart, lungs, joints, and other organs);
• sleep disturbances;
• impotence;
• inflammations.

Rare (may affect up to 1 in 1,000 people)

• leukemia (cancer that affects the blood and bone marrow);
• severe allergic reaction with shock;
• multiple sclerosis;
• nerve disorders (such as optic neuritis and Guillain-Barré syndrome that can cause muscle weakness, abnormal sensations, tingling in the arms and upper body);
• cardiac arrest;
• pulmonary fibrosis (scarring in the lungs);
• intestinal perforation (hole in the intestinal wall);
• hepatitis (inflammation of the liver);
• reactivation of hepatitis B virus;
• autoimmune hepatitis (inflammation of the liver caused by the body's own immune system);
• cutaneous vasculitis (inflammation of blood vessels in the skin);
• Stevens-Johnson syndrome (potentially life-threatening reaction with flu-like symptoms and rash with blisters);
• facial edema associated with allergic reactions;
• erythema multiforme (inflammatory rash on the skin);
• lupus-like syndrome;
• angioedema (localized skin inflammation);
• lichenoid skin reaction (purple-red rash with itching).

Frequency not known (cannot be estimated from the available data)

• hepatosplenic T-cell lymphoma (a rare and often fatal blood cancer);
• Merkel cell carcinoma (a type of skin cancer);
• Kaposi's sarcoma, a rare cancer related to human herpesvirus 8 infection. Kaposi's sarcoma usually occurs more frequently as purple skin lesions;
• liver failure;
• worsening of a disease called dermatomyositis (seen as skin rash accompanied by muscle weakness);
• weight gain (for most patients, weight gain was reduced).

Some side effects observed with adalimumab do not have symptoms and can only be identified through a blood test. These include:

Very common (may affect more than 1 in 10 people)

• low white blood cell count;
• low red blood cell count;
• increased lipids in blood;
• increased liver enzymes.

Common (may affect up to 1 in 10 people)

• high white blood cell count;
• low platelet count;
• increased uric acid in blood;
• abnormal sodium levels in blood;
• low calcium levels in blood;
• low phosphate levels in blood;
• high blood sugar;
• high lactate dehydrogenase levels in blood;
• presence of autoantibodies in blood;
• low potassium levels in blood.

Uncommon (may affect up to 1 in 100 people)

• high bilirubin levels (liver function test).

Rare (may affect up to 1 in 1,000 people)

• low counts in blood for white blood cells, red blood cells, and platelets.

Reporting of side effects

If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can help provide more information on the safety of this medication.

5. Storage of AMGEVITA

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the label and on the carton after EXP or CAD. The expiry date is the last day of the month shown.

Store in a refrigerator (between 2 °C and 8 °C). Do not freeze.

Store in the original package to protect from light.

You may store a single AMGEVITA pre-filled pen at temperatures up to a maximum of 25 °C for a maximum period of 14 days. The pre-filled pen must be protected from light and must be discarded if not used within 14 days.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Package contents and further information

Composition of AMGEVITA

• The active substance is adalimumab. Each pen contains 40 mg of adalimumab in 0.8 ml of solution.
• The other ingredients are glacial acetic acid, sucrose, polysorbate 80, sodium hydroxide, and water for injections.

Appearance and package contents of the product

AMGEVITA is a clear, colorless to slightly yellowish solution.

Each pack contains 1, 2, 4, or 6 single-use SureClick pre-filled pens.

Marketing authorisation holder and manufacturer

Amgen Europe B.V.

Minervum 7061

4817 ZK Breda

Netherlands

Marketing authorisation holder

Amgen Europe B.V.

Minervum 7061

4817 ZK Breda

Netherlands

Manufacturer

Amgen Technology Ireland UC

Pottery Road

Dun Laoghaire

Co. Dublin

Ireland

Manufacturer

Amgen NV

Telecomlaan 5-7

1831 Diegem

Belgium

You can request more information about this medicine from the local representative of the marketing authorisation holder.

Date of last revision of this leaflet:

Other sources of information

Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu.